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Background/aim: Cholesterol ester storage disease (CESD) is one of the rare causes that should be kept in mind in the etiology of cirrhosis.
Recent studies detected that significantly reduced lysosomal acid lipase deficiency enzyme (LAL) in patients with cryptogenic cirrhosis
(CC). Moreover, studies have evaluated that LAL activity is as effective as scoring systems in assessing the severity of cirrhosis.
In this study, we aimed to investigate the CESD with LAL level and mutation analysis of LIPA gene in patients diagnosed with CC and to
compare LAL activities between patients with CC and healthy volunteers.
Materials and methods: Laboratory parameters and cirrhosis stage (CHILD and MELD) were recorded for the patient group included in
the study. In addition, blood samples were taken from each case included in the study for LAL activity determination and LIPA gene analysis.
Results: A statistically significant decrease in LAL activity was found in patients diagnosed with CC compared to the healthy group. LIPA
gene analysis did not detect CESD in any patient group. Correlation analysis showed a positive correlation between LAL activity and white
blood cell and platelet counts in both healthy volunteers and CC patient groups. In the univariate and multivariate logistic regression
analysis of the parameters associated with the MELD of ≥10 in patients with CC, significant relationship was found between the MELD of
≥10 and the LAL activity.
Conclusions: In our study, LAL activity was significantly lower in CC patients than in the normal population. LAL activity level appears to
be a parameter that can be used to assess the severity of cirrhosis.
Key words: Cholesterol ester storage disease, cryptogenic cirrhosis, lysosomal acid lipase deficiency, LIPA gene

1. Introduction
Cholesterol ester storage disease (CESD) is a rare
lysosomal storage disease characterized by a deficiency of
the lysosomal acid lipase enzyme (LAL) activity due to a
mutation in the LIPA gene. It is challenging to diagnose
LAL deficiency in adulthood due to subtle symptoms
and lack of a characteristic marker. On the other hand, a
significant portion of adult patients with LAL deficiency
shows asymptomatic liver enzyme elevation and presents
with fatty liver disease, nonalcoholic steatohepatitis [1,2].
Patients developing cirrhosis due to cholesterol ester
storage disease have been described in the literature [3,4].

Moreover, a recent study reported that the prevalence of
LAL deficiency in unexplained liver diseases is 0.1% [5].
These findings indicate that patients with cryptogenic
cirrhosis (CC) should be examined in terms of CESD.
In addition, although some studies have shown a
decrease in LAL activity in patients with CC, no pathogenic
variation has been detected in the LIPA gene. In a study
conducted in 2016, it was found that LAL activity was
decreased in patients with CC compared to the normal
population [6]. Similarly, Baratta et al. detected lower LAL
activity in cases with a diagnosis of CC compared to the
normal population [7].
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In this study, we aimed to analyze the level of LAL
activity in CC patients and healthy volunteers, to detect
LIPA gene mutations, and to compare the differences in
LAL activity, clinical characteristics, and other laboratory
parameters between these two groups.
2. Materials and methods
The study has been performed between October 2018 and
October 2020. Thirty patients diagnosed with CC and 30
sex and age-matched healthy volunteers were enrolled in
the study. Cryptogenic cirrhosis was defined as cirrhosis
of unknown etiology in patients with a clinical history of
previous overweight/obesity, diabetes, insulin resistance
and/or liver steatosis, and no history of alcoholism or
alcohol consumption higher than 20 g/d in men and 10
g/d in women, or previous acute or chronic viral and
autoimmune hepatitis [8]. The severity of CC was assessed
by the Child-Pugh score (CHILD) and Model for EndStage Liver Disease score (MELD).
Total cholesterol, LDL-cholesterol, HDL-cholesterol,
triglyceride, liver function tests, albumin, and cell blood
count were assessed for all subjects. Abdominal imaging
(ultrasound and magnetic resonance images) and
echocardiographic findings of CC-diagnosed patients
were evaluated.
2.1. Determination of lysosomal acid lipase enzyme
activity by DBS method
The LAL activity was measured by optimizing the method
reported by Dairaku et al. [9]. In brief, 3 mm spots were
eluted in 200 µL of sterile water for 1 h at room temperature.
Inhibited and uninhibited reactions were carried out in 3
replicates for each patient. For inhibited reactions, 40 µL
of blood samples and 10 µL of sterile water were added
to each well. In contrast, for uninhibited reactions, 40 µL
of blood samples and 10 µL of Lalistat 2 were added to
each well, and the total volume in the wells was completed
to 100 µL with substrate buffer. Plates were covered with
adhesive aluminum film and incubated at 37 °C for 24 h.
The reaction was terminated by adding 200 µL of 150 mM
EDTA in the wells. Fluorescence intensity was measured
using the Varioscan Thermo device (Ex/Em: 320/450 nm).
2.2. LIPA gene analysis
2.2.1. DNA isolation protocol:
Blood samples were collected in EDTA tubes, aliquoted,
and stored at –80 °C until DNA isolation. For DNA
isolation, 1 mL blood was mixed with 10 mL Buffer A
(10 mM Tris-HCl, 320 mM sucrose, 5 MgCl2, 1% Triton
X-100, pH 8.0) for 4 min at room temperature. Cells
were pelleted by centrifugation at 3000 rpm for 10 min.
Pellet was resuspended in 5 mL Buffer A and repelleted
by centrifugation at 3000 rpm for 10 min. Two mL Buffer
B (400 mM Tris-HCl, 0.5 M EDTA, 150 mM NaCl, 1%
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SDS) was added to the pellet, and cells were lysed by
pipetting. Five hundred µL sodium perchlorate (NaCl4)
was added and further incubated for 10 min on a shaker
at room temperature. Next, it was incubated at 65 °C for
25 min, with vortexing every 5 min. Two mL chloroform
(at –20 °C) was added and incubated for 10 min on a
shaker. After centrifugation at 3000 rpm for 10 min at +4
°C, the supernatant was transferred to a new tube. Six mL
EtOH (100%) was added and mixed until DNA precipitate
was visible as “medusa”, which was next transferred to
an Eppendorf tube with 500 µL EtOH (70%). DNA was
pelleted by centrifugation at 14000 rpm for 1 min and airdried. DNA was resuspended in 50–100 µL of 5 mM TrisEDTA pH 8.0 and left at +4 °C overnight. The next day, it
was incubated at 55 °C for 1 h and stored at –20 °C.
2.2.2. PCR amplification of LIPA exons from genomic
DNA:
All ten exons of the LIPA gene (Major transcript LIPA202, NM_000234.4, GRCh38.p13) were amplified from
genomic DNA. Primers were designed using NCBI’s
Primer-BLAST tool.
2.2.3. Sanger sequencing and variant interpretation:
PCR products were cleaned up by ExoSAP-IT, and
sequencing PCR was performed using the BigDye
Terminator Kit. Sequencing analysis was performed by
using the ABI 3730 × l DNA Analyzer. Chromatograms
were manually checked using SnapGene 5.2 and aligned
to the reference human genome (GRCh38.p13) using
NCBI-BLAST (BLASTN) tool. Potential pathogenicity of
identified variants was assessed with the help of databases,
including gnomAD, ClinVar, Varsome, and dbSNP,
according to the ACMG guidelines.
2.3. Statistical analysis
The categorical variable (gender) was assessed using chisquare test and expressed as number and percentage.
The Shapiro-Wilk tests were performed to evaluate
the normality of continuous variables. All continuous
variables were expressed as mean ± SD (min-max) and
median. Nonparametric continuous variables were
analyzed with the Mann-Whitney U test, while parametric
continuous variables were assessed with a t-test. Pearson’s
correlation coefficient was used to analyze the associations
between laboratory parameters. The relationship between
laboratory parameters and CC and the MELD score of
≥10 was analyzed by logistic regression. Receiver operator
characteristic (ROC) curve analysis was used to determine
threshold values in the laboratory to establish LAL activity
to differentiate CC and MELD score of ≥10 in patients
with CC. Specificity, sensitivity, and positive and negative
predictive value of LAL activity were determined.
Data were analyzed with the Statistical Package for
Social Sciences (SPSS) software (version 21.0; SPSS,
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Chicago, IL, USA). A two-tailed p-value < 0.05 was
considered significant.
3. Results
Thirty patients with the diagnosis of CC and sex and agematched healthy subjects were enrolled in the study. The
mean age of patients with CC was 53.3 ± 9.9 (28–75) years.
In physical examination, gastrointestinal tract endoscopy,
abdominal ultrasonography, and MRI, esophageal varices
were detected in 26 (86.7%) patients, splenomegaly was
detected in 23 (76.7%), and hepatomegaly was seen in
10 (33.3%) patients. Hepatosteatosis and hepatic fibrosis
were detected in 6 (20%) and 3 (10%) patients, respectively
(Table 1).
A pathogenic variant in the LIPA gene was not found
in any of the cases. In addition, there was no relationship

between the presence of benign variants and LAL activity.
In the assessment of laboratory parameters, higher
ALT, AST, GGT, ALP, total bilirubin, direct bilirubin,
INR, and aPTT levels were found in CC diagnosed
patients compared to healthy subjects. Serum albumin,
total cholesterol, LDL-C and HDL-C levels, and WBC,
hemoglobulin, and platelet counts were found to be lower
in CC diagnosed patients compared to healthy subjects.
There were no differences between the two groups in terms
of serum triglyceride HDL-C levels and MPV (Table 1).
Statistically significantly reduced LAL activity was found
in CC diagnosed patients compared to the healthy group
(Table 1).
Correlation analysis showed positive correlations
between LAL activity and WBC (r = 0.677, p < 0.0001) and
platelet counts (r = 0.566, p = 0.001) in healthy subjects

Table 1. Demographic, clinic and laboratory findings of healthy control group and patients with CC.
Parameters

Healthy group
(n = 30)

Cryptogenic cirrhosis
(n = 30)

p

Age (year)
mean ± SD (min-max)
median

52.9 ± 4.9 (47-63)
52.0

53.3 ± 9.9 (28–75)
54.5

0.397†

Gender (F/M), n (%)

14 (46.7)/16 (53.3)

14 (46.7)/16 (53.3)

1.000

Esophageal varices, n (%)

0 (0)

26 (86.7)

Splenomegaly, n (%)

0 (0)

23 (76.7)

Hepatomegaly, n (%)

0 (0)

10 (33.3)

Intraabdominal acid, n (%)

0 (0)

9 (30.0)

Hepatosteatosis, n (%)

0 (0)

6 (20.0)

Hepatic fibrosis, n (%)

0 (0)

3 (10.0)

CHILD (a/b/c), n (%)

-

21(70.0)/2(6.7)/7(23.3)

ALT (IU/L)
mean ± SD (min-max)
median

20.2 ± 7.9 (15–29)
20.5

28.2 ± 14.5 (9–65)
25.0

<0.0001†

AST (IU/L)
mean ± SD (min-max)
median

20.6 ± 3.9 (15–29)
20.5

41.9 ± 25.8 (19–139)
31.5

<0.0001†

GGT (IU/L)
mean ± SD (min-max)
median

21.2 ± 8.2 (11–44)
21.0

58.7 ± 34.2 (13–170)
52.5

<0.0001†

ALP (IU/L)
mean ± SD (min-max)
median

79.7 ± 19.0 (45–110)
79.0

121.4 ± 75.2 (53–429)
104.5

0.005†

Albumin (mg/dL)
mean ± SD (min-max)
median

4.3 ± 0.2 (3.9–4.6)
4.4

3.6 ± 0.6 (2.1–4.6)
3.7

<0.0001‡
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Total bilirubin (mg/dL)
mean ± SD (min-max)
median

0.7 ± 0.2 (0.4–1.1)
0.6

2.2 ± 2.3 (0.4–12.1)
1.35

<0.0001†

Direct bilirubin (mg/dL)
mean ± SD (min-max)
median

0.09 ± 0.04 (0.01–0.2)
0.09

0.7 ± 1.3 (0.01–7)
2.8

<0.0001†

TC (mg/dL)
mean ± SD (min-max)
median

212.1 ± 33.7 (138.0–298.0)
204.0

176.3 ± 39.0 (93.0–299.0)
172.0

<0.0001†

LDL-C (mg/dL)
mean ± SD (min-max)
median

134.2 ± 24.7 (77.0–191.0)
134.5

111.2 ± 33.1 (51.0–200.0)
107.0

0.002†

HDL-C (mg/dL)
mean ± SD (min-max)
median

50.1 ± 14.5 (28.0–87.0)
45.0

42.6 ± 13.3 (23.0–73.0)
42.0

0.058†

Triglyceride (mg/dL)
mean ± SD (min-max)
median

116.9 ± 56.6 (57–245)
98.5

111.4 ± 70.5 (23–370)
98.5

0.549†

WBC (103/μL)
mean ± SD (min-max)
median

7.8 ± 2.2 (4.1–12.5)
7.9

5.1 ± 1.8 (1.9–9.2)
4.9

<0.0001‡

Hemoglobin (g/dL)
mean ± SD (min-max)
median

13.7 ± 1.4 (11.6–16.4)
13.9

11.8 ± 2.2 (7.6–15.8)
11.9

<0.0001‡

Platelets (103/μL)
mean ± SD (min-max)
median

199.9 ± 51.7 (123–341)
184.5

110.9 ± 58.4 (40–270)
93.0

<0.0001†

MPV (fL)
mean ± SD (min-max)
median

8.7 ± 1.1 (6.7–11.4)
8.6

9.0 ± 0.9 (6.6–11.2)
8.9

0.325‡

INR
mean ± SD (min-max)
median

0.91 ± 0.09 (0.78–1.20)
0.9

1.22 ± 0.26 (0.90–2.00)
1.2

<0.0001†

aPTT (second)
mean ± SD (min-max)
median

29.2 ± 2.2 (25.5–33.3)
28.9

36.3 ± 7.1 (25.9–54.8)
35.0

<0.0001†

LAL activity (nmol/spot/h)
mean ± SD (min-max)
median

0.45 ± 0.14 (0.19–0.82)
0.47

0.34 ± 0.21 (0.06–0.87)
0.30

0.019‡

: Mann Whitney U test, ‡: student’s t-test, ALT: alanine aminotransferase, ALP: alkaline phosphatase, aPTT: activated partial
thromboplastin time, AST: aspartate aminotransferase, GGT: gamma glutamyl transferase, HDL-C: high-density lipoprotein
cholesterol, INR: international normalized ratio, LAL: lysosomal acid lipase enzyme, LDL-C: low-density lipoprotein cholesterol,
min: minimum, max: maximum, MPV: mean platelet volume, SD: standard deviation, TC: total cholesterol, WBC: white blood
cell.
†
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(Figure a, b). Positive correlations between LAL activity
and WBC (r = 0.527, p = 0.003) and platelet counts (r
= 0.599, p < 0.0001) were detected in patients with CC
(Figure c, d). In patients with CC, a statistically significant
negative correlation between MELD score and LAL
activity was revealed (r = –0.409, p = 0.025) (Figure e).
Univariate and multivariate logistic regression analysis was performed to determine parameters associated
with CC. Associations between CC and WBC [OR: 0.998
(0.996–1.000), p = 0.034], albumin [OR: 0.0001 (0.0001–
0.370), p = 0.038] and INR [8.257 × 1018 (3.498–1.949 ×
1037, p = 0.044)] were determined (Table 2).
Univariate and multivariate logistic regression analysis showed that INR [245165746 (7.365–8.161 × 1015),
p=0.029] and LAL activity [0.0001 (0.0001–0345), p =
0.034] were associated with the MELD score of ≥10 in patients with CC (Table 3).
The diagnostic value of LAL activity for the prediction
of CC was assessed with ROC analysis. Lysosomal acid

lipase DBS activity ≤0.419 nmol/spot/h was almost
identical with regard to best prediction of CC. Sensitivity
and specificity of LAL activity were 70% (50.6%–80.3%)
and 66.7% (47.2%–82.7%), respectively (Table 4).
ROC analysis was performed to calculate the diagnostic
value of LAL activity for the prediction of MELD score ≥10
in patients with CC. Lysosomal acid lipase enzyme activity
≤0.396 nmol/spot/h was almost identical with regard to
best prediction of MELD score ≥10 in patients with CC.
Sensitivity and specificity of LAL activity for prediction of
MELD score ≥10 was determined as 86.7% (59.5%–98.3%)
and 60.0% (32.3%–83.7%), respectively (Table 5).
4. Discussion
Our study is one of the rare studies investigating the
relationship between LAL activity and CC and the possible
presence of CESD in patients with CC. The most important
finding of this study is that the patients with CC have lower
LAL activity compared to the healthy population. Due

Table 2. Univariate and multivariate logistic regression analysis of parameters related with CC.
Univariate regression model

Multivariate regression model

OR
(95% Cl Lower-upper)

p

OR
(95% Cl Lower-upper)

p

Age (year)

1.007
(0.943–1.075)

0.841

LAL activity (nmol/spot/h)

0.29
(0.001–0.629)

0.024

WBC (103/μL)

0.999
(0.999–1.000)

<0.0001

0.998
(0.996–1.000)

0.034

Platelets (103/μL)

1.000
(1.000–1.000)

<0.0001

ALT (IU/L)

1.069
(1.010–1.130)

0.02

AST (IU/L)

1.346
(1.149–1.575)

<0.0001

GGT (IU/L)

1.133
(1.060–1.211)

<0.0001

ALP (IU/L)

1.032
(1.009–1.055)

0.006

Albumin (mg/dL)

0.001
(0.0001–0.037)

<0.0001

0.0001
(0.0001–0.370)

0.038

Total bilirubin (mg/dL)

8979.518
(19.521–39625.945)

<0.0001

Direct bilirubin (mg/dL)

2.066 × 109
(13354.383–3.195 × 1014)

<0.0001

TC (mg/dL)

0.971
(0.954–0.989)

0.002

Parameters
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LDL-C (mg/dL)

0.973
(0.954–0.992)

0.007

HDL-C (mg/dL)

0.960
(0.922–1.000)

0.049

Triglyceride (mg/dL)

0.999
(0.954–1.007)

0.732

Hemoglobin (g/dL)

0.558
(0.391–0.796)

0.001

MPV (fL)

1.295
(0.778–2.154)

0.320

INR

3691465.64
(2051.491–6.642 × 109)

<0.0001

aPTT (second)

1.538
(1.224–1.932)

<0.0001

8.257 x 1018
(3.498–1.949 × 1037)

0.044

ALT: alanine aminotransferase, ALP: alkaline phosphatase, aPTT: activated partial thromboplastin time, AST: aspartate
aminotransferase, Cl: confidence intervals, GGT: gamma glutamyl transferase, HDL-C: high-density lipoprotein cholesterol,
INR: international normalized ratio, LAL: lysosomal acid lipase enzyme, LDL-C: low-density lipoprotein cholesterol, MPV:
mean platelet volume, OR: odds ratio TC: total cholesterol, WBC: white blood cell.

Figure: Correlation analysis of laboratory parameters in healthy group (a) LAL (nmol/spot/h) level and WBC (r = 0.677, p <
0.0001), (b) LAL (nmol/spot/h) and platelets (r = 0.566, p = 0.001). Correlation analysis of laboratory parameters in patients
with CC (c) LAL (nmol/spot/h) level and WBC (r = 0.527, p = 0.003), (d) LAL (nmol/spot/h) and platelets (r = 0.599, p <
0.0001), (e) LAL (nmol/spot/h) level and MELD score (r = –0.409, p = 0.025) in patients with CC.
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Table 3. Univariate and multivariate logistic regression analysis of parameters related with MELD score ≥10 in
patients with CC.

Parameters

Univariate regression model

Multivariate regression model

OR
p
(95% Cl Lower-upper)

OR
p
(95% Cl Lower-upper)

Age (year)

0.936
(0.857–1.023)

0.146

LAL activity (nmol/spot/h)

0.007
(0.0001–0.656)

0.032

WBC (103/μL)

1.000
(0.999–1.000)

0.549

Platelets (103/μL)

1.000
(1.000–1.000)

0.098

ALT (IU/L)

1.003
(0.954–1.055)

0.899

AST (IU/L)

1.039
(0.994–1.086)

0.089

GGT (IU/L)

1.010
(0.987–1.033)

0.899

ALP (IU/L)

1.009
(0.995–1.024)

0.206

Albumin (mg/dL)

0.101
(0.016–0.628)

0.014

Total bilirubin (mg/dL)

332.980
(1.931–57412.384)

0.027

Direct bilirubin (mg/dL)

3861146.34
(2.700–5.522 × 1012)

0.036

TC (mg/dL)

0.993
(0.974-1.013)

0.480

LDL-C (mg/dL)

0.998
(0.976–1.020)

0.862

HDL-C (mg/dL)

1.016
(0.961–1.074)

0.588

Triglyceride (mg/dL)

0.992
(0.980–1.005)

0.247

Hemoglobin (g/dL)

0.675
(0.453–1.007)

0.054

MPV (fL)

1.153
(0.548–2.425)

0.707

INR

130315.050
(14.607–1.163 × 109)

0.011

aPTT (second)

1.116
(0.984–1.266)

0.087

0.0001
(0.0001–0345)

0.034

245165746
(7.365–8.161 × 1015)

0.029

ALT: alanine aminotransferase, ALP: alkaline phosphatase, aPTT: activated partial thromboplastin time, AST:
aspartate aminotransferase, Cl: confidence intervals GGT: gamma glutamyl transferase, HDL-C: high-density
lipoprotein cholesterol, INR: international normalized ratio, LAL: lysosomal acid lipase enzyme, LDL-C: lowdensity lipoprotein cholesterol, MPV: mean platelet volume, OR: odds ratio TC: total cholesterol, WBC: white
blood cell.
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Table 4. Diagnostic value and ROC analysis of LAL enzyme activity for prediction of CC.

Parameters

Sensitivity (%) Specificity (%) PPV (%)
(95% Cl)
(95% Cl)
(95% Cl)

LAL activity (nmol/spot/h) 70.0
≤ 0.419 nmol/spot/h
(50.6–80.3)

66.7
(47.2–82.7)

NPV (%)
(95% Cl)

67.7
68.9
(54.6–78.6) (54.9–80.2)

Accuracy
(%)
(95% Cl)

ROC analysis
AUC
(95% Cl)

68.3
0.677
(55.0–79.7) (0.537–0.817)

p
0.019

AUC: area under curve, Cl: confidence intervals, LAL: lysosomal acid lipase, NPV: negative predictive value, PPV: positive predictive
value, ROC: receiver operating characteristic.
Table 5. Diagnostic value and ROC analysis of LAL enzyme activity for prediction of MELD score ≥10 in patients with CC.

Parameters

Sensitivity (%) Specificity (%) PPV (%)
(95% Cl)
(95% Cl)
(95% Cl)

LAL activity (nmol/spot/h)
≤ 0.396 nmol/spot/h

86.7
(59.5–98.3)

60.0
(32.3–83.7)

NPV (%)
(95% Cl)

Accuracy
(%)
(95% Cl)

ROC analysis
AUC
(95% Cl)

68.42
81.8
73.3
0.756
(53.1–80.6) (53.7–87.7) (54.1–87.7) (0.573–0.938)

p
0.017

AUC: area under curve, Cl: confidence intervals, LAL: lysosomal acid lipase enzyme, NPV: negative predictive value, PPV: positive
predictive value, ROC: receiver operating characteristic.

to the detection of no pathogenic variation of the LIPA
gene, the lower LAL activity of CC diagnosed patients
was not associated with cholesterol ester storage disease.
Consistently, a study determined reduced LAL activity
in patients with CC relative to the healthy subjects [6].
Moreover, in a study involving 60 patients with CC and
100 healthy volunteers, Baratta et al. reported that CC
diagnosed patients have lower LAL activity compared to
the healthy population [7].
As expected, most of the LAL activity is dosed in
DBS derives from the leukocyte, and it is suggested that
the low leukocyte count detected in cirrhosis patients
leads to a decrease in LAL activity [6,10]. In our study,
a positive significant correlation was detected between
LAL activity and WBC in both groups. Interestingly, the
same relationship between enzyme activity and platelets
was determined in both the previous and our study [6].
Although thrombocytes are known to contain lysosomes,
it is thought that contribution of lysosomal enzyme
activity in thrombocytes is restricted in the DBS method.
Thrombocytopenia is associated with the severity of
cirrhosis, and severe cirrhosis may cause low LAL activity.
However, this hypothesis cannot explain the relationship
between enzyme activity and platelets in a healthy group.
Cholesterol ester storage disease is one of the rare
causes that should be kept in mind in the etiology of
cirrhosis. According to a recent study, the prevalence
of LAL deficiency in unexplained liver diseases was
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reported as 0.1% [5]. Previously, cholesterol ester storage
disease has been described as an etiology of cirrhosis
[3,4]. Although low LAL activity creates confusion in
the possible underlying cholesterol ester storage disease
in cirrhosis patients of unknown etiology, these patients
should be genetically evaluated for LAL deficiency. In our
study, no diagnosis of cholesterol ester storage disease
was made in any patient with CC. In our opinion, the
small size of our study group and the fact that our study
was conducted in a single-center caused this situation.
We believe that multicenter studies with larger number
of patients are needed to determine the prevalence of
cholesterol ester storage disease in cirrhosis patients of
unknown etiology.
Not surprisingly, in cirrhosis patients, deterioration in
liver function tests, decreased leukocyte and platelet count,
and impaired bleeding profile are expected laboratory
findings. In this respect, a significant difference was
found between the two groups when compared with the
healthy control group. In the analysis of the relationship
between laboratory findings and LAL activity, our study
revealed a significant positive correlation with both WBC
and platelet counts. Likewise, Vespasiani-Gentilucci et
al. detected a positive correlation between platelet count
and LAL activity in healthy volunteers. Furthermore, they
determined a positive correlation between enzyme activity
and WBC and platelet counts in CC diagnosed patients
[6]. Similarly, in another study, a significant positive
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correlation was found between LAL activity and white
blood cell and platelet count [11].
There are different scoring systems (CHILD, MELD)
used to determine the severity of cirrhosis [12]. Several
studies have evaluated whether LAL activity is as effective
as these scoring systems in assessing the severity of
cirrhosis, and contrasting results have been reported
[11,13,14]. While a publication revealed no relationship
between LAL activity and cirrhosis severity [14], a weak
significant association was found in some studies [11,13].
In the study conducted by Angelico et al., a weakly
significant correlation was found between the CHILD
and MELD scoring and LAL activity [11]. We detected a
significant positive correlation between the MELD score
and LAL activity. To date, prediction of MELD score ≥10
with LAL activity had not been evaluated in literature.
LAL activity was found to have 87% sensitivity and 60%
specificity in predicting patients with a MELD score of 10
and above. These findings suggest that LAL activity may be
effective in determining the severity of cirrhosis.
The effectiveness of LAL enzyme activity as a parameter
to predict CC has been evaluated in a recent study [14].
Gravito-Soares et al. stated that LAL activity could be used
in the diagnosis of CC disease. It was determined that LAL
activity could diagnose CC with 86.2% sensitivity and 75%
specificity [14]. Although the values in our study are not
as high as reported, it was calculated that LAL activity
predicted the diagnosis of CC with 70% sensitivity and
67% specificity.
In this study, the small number of subgroups and
the lack of a prospective follow-up period limited the
evaluation of the effectiveness of LAL activity in predicting
CC and determining the severity of CC.

In conclusion, LAL activity was found to be significantly
lower in CC patients compared to the healthy population.
The level of LAL activity appears to be a parameter that can
be used to assess the severity of cirrhosis. Although CESD
was not detected by genetic analysis in any of our patients
with CC, the cases reported in the literature suggest that
CESD should be investigated in patients with CC. Future
longitudinal prospective studies with larger sample sizes
are needed to confirm our findings.
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